Breaking News

CSL Licenses Selexis Cell Line

CSL to use SUREtechnology for antibody

CSL Ltd. has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody for Phase I clinical trials. Under the agreement, CSL has rights to use a cell line generated using the Selexis SUREtechnology Platform for the cGMP production of an undisclosed antibody.

“We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform,” said Dr. Igor Fisch, chief executive officer, Selexis SA. “This agreement represents Selexis’ commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters